Work

CYCLONE 1: A phase 2 study of abemaciclib in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a novel hormonal agent and taxane-based chemotherapy.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.tps5086

Authors: Neeraj Agarwal, Stephane Oudard, Josep M. Piulats, Michael Thomas Schweizer, Aude Flechon, Teresa Alonso Gordoa, Karim Nacerddine, Andrew Lithio, Erica L. Johnston, Matthew Raymond Smith

Institutions: University of Utah, Huntsman Cancer Institute, Hôpital Européen Georges-Pompidou, Institut Català d'Oncologia, Duran i Reynals Hospital, University of Washington, Fred Hutch Cancer Center, Centre Léon Bérard, Hospital Universitario Ramón y Cajal, Eli Lilly (United States), Massachusetts General Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3170163871

Cites:

Cited by: 1

Related to: 10